Show simple item record

dc.contributor.advisorSkrepnek, Granten
dc.contributor.authorYamauchi, Phillip*
dc.date.accessioned2017-06-26T18:18:20Z
dc.date.available2017-06-26T18:18:20Z
dc.date.issued2007
dc.identifier.urihttp://hdl.handle.net/10150/624415
dc.descriptionClass of 2007 Abstracten
dc.description.abstractObjectives: To evaluate the efficacy of carmustine wafers over placebo plus surgery in the treatment of primary glioblastoma multiforme. Methods: Searches of MEDLINE (1966-2007), ASH (American Society of Hematology) abstracts, and ASCO (American Society of Clinical Oncology) abstracts were conducted to obtain clinical outcomes data (meta- analysis, randomized controlled studies) for the carmustine wafers or for the traditional form of therapy, surgical resection of glioblastoma multiforme. Serious adverse events associated with the chemotherapeutic agent were identified and their respective rates of incidence calculated. Three prospective randomized controlled trials were used to provide point estimates and distributions for the Monte Carlo simulation. Parameters used to populate the Markov model were derived from the extant primary literature for patients undergoing surgical resection with either carmustine or placebo for glioblastoma multiforme. The base case was a 50 year old male with primary glioma. Results: Findings indicated that carmustine wafers increased survival over placebo from 54.05 months [95% confidence interval 46.25-61.07] to 69.87 months [95% confidence interval 67.02-71.94]. Serious side effects such as intracranial hemorrhage, seizures, and infections were also taken into account in the decision analytic model. Conclusions: Carmustine wafers significantly increase survival in patients undergoing surgical resection for glioblastoma multiforme. Therefore, carmustine wafers should be used as an adjunct to surgery in these patients.
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectCarmustine Wafersen
dc.subjectGlioblastoma Multiformeen
dc.subject.meshCarmustineen
dc.subject.meshGlioblastomaen
dc.subject.meshDrug Therapyen
dc.titleAn Outcomes Analysis of Carmustine Wafers with Surgery versus Placebo Wafers with Surgery in the Treatment of Glioblastoma Multiformeen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
html.description.abstractObjectives: To evaluate the efficacy of carmustine wafers over placebo plus surgery in the treatment of primary glioblastoma multiforme. Methods: Searches of MEDLINE (1966-2007), ASH (American Society of Hematology) abstracts, and ASCO (American Society of Clinical Oncology) abstracts were conducted to obtain clinical outcomes data (meta- analysis, randomized controlled studies) for the carmustine wafers or for the traditional form of therapy, surgical resection of glioblastoma multiforme. Serious adverse events associated with the chemotherapeutic agent were identified and their respective rates of incidence calculated. Three prospective randomized controlled trials were used to provide point estimates and distributions for the Monte Carlo simulation. Parameters used to populate the Markov model were derived from the extant primary literature for patients undergoing surgical resection with either carmustine or placebo for glioblastoma multiforme. The base case was a 50 year old male with primary glioma. Results: Findings indicated that carmustine wafers increased survival over placebo from 54.05 months [95% confidence interval 46.25-61.07] to 69.87 months [95% confidence interval 67.02-71.94]. Serious side effects such as intracranial hemorrhage, seizures, and infections were also taken into account in the decision analytic model. Conclusions: Carmustine wafers significantly increase survival in patients undergoing surgical resection for glioblastoma multiforme. Therefore, carmustine wafers should be used as an adjunct to surgery in these patients.


This item appears in the following Collection(s)

Show simple item record